Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China

In this study, we analyze the cost-effectiveness of fruquintinib as third-line treatment for patients with metastatic colorectal cancer in China, especially after a recent price drop suggested by the National ...

Source: BMC Cancer - October 13, 2020 Category: Cancer & Oncology Authors: Zhi Peng, Xingduo Hou, Yangmu Huang, Tong Xie and Xinyang Hua Tags: Research article Source Type: research